HCC
MCID: HPT023
MIFTS: 95

Hepatocellular Carcinoma (HCC)

Categories: Cancer diseases, Gastrointestinal diseases, Genetic diseases, Liver diseases, Rare diseases

Aliases & Classifications for Hepatocellular Carcinoma

MalaCards integrated aliases for Hepatocellular Carcinoma:

Name: Hepatocellular Carcinoma 57 12 73 58 72 36 29 54 6 15 37 17
Liver Cancer 57 12 72 42 15
Primary Liver Cancer 12 20 15
Liver Neoplasms 73 44 70
Hepatoma 57 12 72
Hcc 57 58 72
Rare Tumor of Liver and Intrahepatic Biliary Tract 20 58
Primary Malignant Neoplasm of Liver 12 70
Malignant Neoplasm of Liver 12 70
Hepatoblastoma, Somatic 57 13
Cancer, Hepatocellular 57 39
Liver Cell Carcinoma 57 72
Hepatic Cancer 12 54
Hepatoblastoma 58 70
Lcc 57 72
Malignant Neoplasm of Liver, Not Specified As Primary or Secondary 12
Hepatocellular Carcinoma, Childhood Type, Somatic 57
Non-Resectable Primary Hepatic Malignant Neoplasm 12
Liver and Intrahepatic Biliary Tract Carcinoma 70
Resectable Malignant Neoplasm of the Liver 12
Childhood-Onset Hepatocellular Carcinoma 58
Adult Primary Hepatocellular Carcinoma 70
Resectable Malignant Neoplasm of Liver 12
Malignant Neoplasm of Liver, Primary 12
Pediatric Hepatocellular Carcinoma 58
Hepatocellular Carcinoma, Somatic 57
Malignant Hepato-Biliary Neoplasm 12
Primary Malignant Liver Neoplasm 20
Malignant Hepatobiliary Neoplasm 70
Hepatocellular Cancer, Somatic 57
Adult Hepatocellular Carcinoma 58
Rare Tumor of Liver and Ibt 58
Primary Tumor of the Liver 20
Liver Cell Carcinoma; Lcc 57
Carcinoma, Hepatocellular 44
Malignant Tumor of Liver 12
Primary Cancer of Liver 20
Primary Liver Carcinoma 20
Hepatocellular Cancer 72
Neoplasm of the Liver 6
Childhood-Onset Hcc 58
Ca Liver - Primary 12
Neoplasm of Liver 12
Hepatic Neoplasm 12
Liver Carcinoma 70
Liver Neoplasm 17
Pediatric Hcc 58
Adult Hcc 58
Hepatomas 15

Characteristics:

Orphanet epidemiological data:

58
hepatocellular carcinoma
Inheritance: Not applicable; Prevalence: 1-9/100000 (United States),1-5/10000 (Europe); Age of onset: All ages; Age of death: adult;
hepatoblastoma
Inheritance: Not applicable; Prevalence: <1/1000000 (Europe),1-9/1000000 (Europe); Age of onset: Childhood,Infancy,Neonatal; Age of death: early childhood,infantile;
adult hepatocellular carcinoma
Inheritance: Not applicable;
pediatric hepatocellular carcinoma
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe),<1/1000000 (United States); Age of onset: Adolescent,Childhood; Age of death: adolescent,adult,early childhood,late childhood,young Adult;

OMIM®:

57 (Updated 20-May-2021)
Inheritance:
somatic mutation

Miscellaneous:
genetic heterogeneity


HPO:

31
hepatocellular carcinoma:
Inheritance somatic mutation heterogeneous


Classifications:

Orphanet: 58  
Rare hepatic diseases


Summaries for Hepatocellular Carcinoma

MedlinePlus : 42 Your liver is the largest organ inside your body. It helps your body digest food, store energy, and remove poisons. Primary liver cancer starts in the liver. Metastatic liver cancer starts somewhere else and spreads to your liver. Risk factors for primary liver cancer include Having hepatitis B or C Heavy alcohol use Having cirrhosis, or scarring of the liver Having hemochromatosis, an iron storage disease Obesity and diabetes Symptoms can include a lump or pain on the right side of your abdomen and yellowing of the skin. However, you may not have symptoms until the cancer is advanced. This makes it harder to treat. Doctors use tests that examine the liver and the blood to diagnose liver cancer. Treatment options include surgery, radiation, chemotherapy, or liver transplantation. NIH: National Cancer Institute

MalaCards based summary : Hepatocellular Carcinoma, also known as liver cancer, is related to adult hepatocellular carcinoma and non-alcoholic fatty liver disease, and has symptoms including nausea and vomiting, constipation and fever. An important gene associated with Hepatocellular Carcinoma is PIK3CA (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha), and among its related pathways/superpathways are Hepatocellular carcinoma and Viral carcinogenesis. The drugs Ethiodized oil and Tegafur have been mentioned in the context of this disorder. Affiliated tissues include liver, t cells and bone, and related phenotypes are hepatomegaly and portal hypertension

Disease Ontology : 12 A liver carcinoma that has material basis in undifferentiated hepatocytes and located in the liver.

OMIM® : 57 Hepatocellular carcinoma is the major histologic type of malignant primary liver neoplasm. It is the fifth most common cancer and the third most common cause of death from cancer worldwide. The major risk factors for HCC are chronic hepatitis B virus (HBV) infection, chronic hepatitis C virus (HCV) infection, prolonged dietary aflatoxin exposure, alcoholic cirrhosis, and cirrhosis due to other causes. Hepatoblastomas comprise 1 to 2% of all malignant neoplasms of childhood, most often occurring in children under 3 years of age. Hepatoblastomas are thought to be derived from undifferentiated hepatocytes (Taniguchi et al., 2002). (114550) (Updated 20-May-2021)

KEGG : 36 Hepatocellular carcinoma (HCC) is a major type of primary liver cancer and one of the rare human neoplasms etiologically linked to viral factors. It has been shown that, after HBV/HCV infection and alcohol or aflatoxin B1 exposure, genetic and epigenetic changes occur. The recurrent mutated genes were found to be highly enriched in multiple key driver signaling processes, including telomere maintenance, TP53, cell cycle regulation, the Wnt/beta-catenin pathway (CTNNB1 and AXIN1), the phosphatidylinositol-3 kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway. Recent studies using whole-exome sequencing have revealed recurrent mutations in new driver genes involved in the chromatin remodelling (ARID1A and ARID2) and the oxidative stress (NFE2L2) pathways.

UniProtKB/Swiss-Prot : 72 Hepatocellular carcinoma: A primary malignant neoplasm of epithelial liver cells. The major risk factors for HCC are chronic hepatitis B virus (HBV) infection, chronic hepatitis C virus (HCV) infection, prolonged dietary aflatoxin exposure, alcoholic cirrhosis, and cirrhosis due to other causes.

Wikipedia : 73 Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer in adults and is... more...

Related Diseases for Hepatocellular Carcinoma

Diseases in the Hepatocellular Carcinoma family:

Adult Hepatocellular Carcinoma

Diseases related to Hepatocellular Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1649)
# Related Disease Score Top Affiliating Genes
1 adult hepatocellular carcinoma 34.4 TP53 TERT PIK3CA PDGFRL IGF2R CTNNB1
2 non-alcoholic fatty liver disease 33.7 TP53 MIR34A MIR27A MIR21 MIR17 MIR155
3 cholangiocarcinoma 33.6 TP53 TERT PIK3CA MIR21 MET CTNNB1
4 colorectal cancer 33.5 TP53 TERT PIK3CA PDGFRL MIR93 MIR34A
5 gastric cancer 33.5 TP53 TERT PIK3CA MIR93 MIR34A MIR27A
6 hepatitis b 33.4 TP53 PIK3CA MIR21 MIR17
7 lung cancer 33.3 TP53 TERT PIK3CA MIR93 MIR34A MIR27A
8 pancreatic cancer 33.1 TP53 TERT PIK3CA MIR34A MIR221 MIR21
9 renal cell carcinoma, nonpapillary 33.1 TP53 PIK3CA MIR93 MIR34A MIR27A MIR224
10 non-alcoholic steatohepatitis 33.0 TP53 MIR34A MIR21 MIR122
11 prostate cancer 33.0 TP53 TERT PIK3CA MIR34A MIR27A MIR224
12 melanoma 33.0 TP53 TERT PIK3CA MIR34A MIR27A MIR224
13 ovarian cancer 32.9 TP53 TERT PIK3CA MIR34A MIR27A MIR221
14 leukemia, acute myeloid 32.9 TP53 TERT PIK3CA MIR34A MIR27A MIR221
15 esophageal cancer 32.9 TP53 TERT PIK3CA MIR93 MIR34A MIR21
16 breast cancer 32.9 TP53 TERT PIK3CA MIR34A MIR27A MIR221
17 bladder cancer 32.8 TP53 TERT PIK3CA MIR93 MIR34A MIR224
18 lung cancer susceptibility 3 32.8 TP53 TERT PIK3CA MIR21 MIR17 MET
19 hepatoblastoma 32.8 TP53 TERT MET CTNNB1 APC
20 intrahepatic cholangiocarcinoma 32.8 TP53 CTNNB1 APC
21 b-cell lymphoma 32.8 TP53 MIR34A MIR21 MIR17 MIR155 CASP8
22 diabetes mellitus 32.8 TP53 PIK3CA MIR34A MIR27A MIR17 MIR155
23 neuroblastoma 32.7 TP53 TERT PIK3CA MIR93 MIR34A MIR221
24 body mass index quantitative trait locus 11 32.6 MIR93 MIR34A MIR27A MIR221 MIR21 MIR17
25 adenoma 32.6 TP53 PIK3CA CTNNB1 APC
26 adenocarcinoma 32.6 TP53 PIK3CA MET CTNNB1 APC
27 glioblastoma 32.5 TP53 TERT PIK3CA MIR34A MIR221 MIR21
28 lymphoma, non-hodgkin, familial 32.5 TP53 PIK3CA MIR34A MIR27A MIR21 MIR17
29 oral squamous cell carcinoma 32.4 TP53 MIR34A MIR27A MIR224 MIR221 MIR21
30 cervical cancer 32.4 TP53 TERT PIK3CA MIR93 MIR34A MIR224
31 primary biliary cholangitis 32.4 MIR21 MIR17 MIR155 MIR122
32 myeloma, multiple 32.3 TP53 PIK3CA MIR93 MIR27A MIR21 MIR17
33 nasopharyngeal carcinoma 32.3 TP53 TERT PIK3CA MIR93 MIR21 MIR17
34 peripheral nervous system disease 32.2 TP53 MIR34A MIR27A MIR21 MIR17 MIR146A
35 bile duct cancer 32.2 TP53 MIR21 MIR17 MET CTNNB1 APC
36 disease by infectious agent 32.2 MIR93 MIR34A MIR27A MIR221 MIR21 MIR17
37 immune deficiency disease 32.2 MIR34A MIR27A MIR21 MIR17 MIR155 MIR146A
38 kidney cancer 32.2 TP53 PIK3CA MIR27A MIR21 MIR17 MIR122
39 medulloblastoma 32.2 TP53 TERT PIK3CA MIR34A MIR17 MET
40 skin carcinoma 32.2 TP53 TERT PIK3CA MIR34A MIR21 MIR17
41 leukemia, chronic lymphocytic 32.1 TP53 MIR34A MIR27A MIR221 MIR21 MIR17
42 endometrial cancer 32.1 TP53 TERT PIK3CA MIR34A MIR27A CTNNB1
43 gallbladder cancer 32.1 TP53 TERT PIK3CA MET CTNNB1
44 pancreatic ductal adenocarcinoma 32.1 TP53 MIR93 MIR224 MIR221 MIR21 MIR155
45 gastrointestinal system disease 32.1 MIR93 MIR34A MIR27A MIR224 MIR221 MIR21
46 familial adenomatous polyposis 32.1 TP53 CTNNB1 AXIN1 APC
47 glioma 32.1 TP53 PIK3CA MIR34A MIR221 MIR21 MIR17
48 rhabdomyosarcoma 32.1 TP53 PIK3CA MIR27A MET IGF2R CTNNB1
49 colon adenocarcinoma 32.0 TP53 PIK3CA MIR21 CTNNB1 CASP8 APC
50 leukemia, acute lymphoblastic 32.0 TP53 MIR27A MIR221 MIR21 MIR17 MIR155

Comorbidity relations with Hepatocellular Carcinoma via Phenotypic Disease Network (PDN):


Active Peptic Ulcer Disease Acute Cystitis
Alcoholic Liver Cirrhosis Deficiency Anemia
Hepatic Encephalopathy Intrahepatic Gall Duct Cancer
Portal Hypertension Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Hepatocellular Carcinoma:



Diseases related to Hepatocellular Carcinoma

Symptoms & Phenotypes for Hepatocellular Carcinoma

Human phenotypes related to Hepatocellular Carcinoma:

58 31 (show top 50) (show all 54)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 hepatomegaly 58 31 hallmark (90%) Very frequent (99-80%),Very frequent (99-80%) HP:0002240
2 portal hypertension 58 31 hallmark (90%) Very frequent (99-80%) HP:0001409
3 abdominal pain 58 31 hallmark (90%) Very frequent (99-80%),Very frequent (99-80%) HP:0002027
4 hyperbilirubinemia 58 31 hallmark (90%) Very frequent (99-80%) HP:0002904
5 hypoalbuminemia 58 31 hallmark (90%) Very frequent (99-80%) HP:0003073
6 type ii diabetes mellitus 58 31 frequent (33%) Frequent (79-30%) HP:0005978
7 elevated hepatic transaminase 58 31 frequent (33%) Frequent (79-30%) HP:0002910
8 anorexia 58 31 frequent (33%) Frequent (79-30%) HP:0002039
9 weight loss 58 31 frequent (33%) Frequent (79-30%) HP:0001824
10 esophageal varix 58 31 frequent (33%) Frequent (79-30%) HP:0002040
11 venous insufficiency 58 31 frequent (33%) Frequent (79-30%) HP:0005293
12 abdominal distention 58 31 frequent (33%) Frequent (79-30%) HP:0003270
13 epigastric pain 58 31 frequent (33%) Frequent (79-30%),Frequent (79-30%) HP:0410019
14 abnormal rectum morphology 31 frequent (33%) HP:0002034
15 hypokalemia 58 31 occasional (7.5%) Occasional (29-5%) HP:0002900
16 fatigue 58 31 occasional (7.5%) Occasional (29-5%),Frequent (79-30%) HP:0012378
17 fever 58 31 occasional (7.5%) Occasional (29-5%) HP:0001945
18 hypoglycemia 58 31 occasional (7.5%) Occasional (29-5%) HP:0001943
19 anemia 58 31 occasional (7.5%) Occasional (29-5%) HP:0001903
20 ascites 58 31 occasional (7.5%) Occasional (29-5%) HP:0001541
21 thrombocytopenia 58 31 occasional (7.5%) Occasional (29-5%) HP:0001873
22 jaundice 58 31 occasional (7.5%) Occasional (29-5%) HP:0000952
23 dyspnea 58 31 occasional (7.5%) Occasional (29-5%) HP:0002094
24 neoplasm 58 31 occasional (7.5%) Occasional (29-5%) HP:0002664
25 hyponatremia 58 31 occasional (7.5%) Occasional (29-5%) HP:0002902
26 hypercalcemia 58 31 occasional (7.5%) Occasional (29-5%) HP:0003072
27 internal hemorrhage 58 31 occasional (7.5%) Occasional (29-5%) HP:0011029
28 polycythemia 58 31 occasional (7.5%) Occasional (29-5%) HP:0001901
29 bone pain 58 31 occasional (7.5%) Occasional (29-5%) HP:0002653
30 diarrhea 58 31 occasional (7.5%) Occasional (29-5%) HP:0002014
31 pedal edema 58 31 occasional (7.5%) Occasional (29-5%) HP:0010741
32 poor appetite 58 31 occasional (7.5%) Occasional (29-5%) HP:0004396
33 thrombocytosis 58 31 occasional (7.5%) Occasional (29-5%) HP:0001894
34 metabolic alkalosis 58 31 occasional (7.5%) Occasional (29-5%) HP:0200114
35 mood changes 58 31 occasional (7.5%) Occasional (29-5%) HP:0001575
36 hepatic encephalopathy 58 31 occasional (7.5%) Occasional (29-5%) HP:0002480
37 hepatic necrosis 58 31 occasional (7.5%) Occasional (29-5%),Frequent (79-30%) HP:0002605
38 anasarca 58 31 occasional (7.5%) Occasional (29-5%) HP:0012050
39 hemobilia 58 31 occasional (7.5%) Occasional (29-5%) HP:0100762
40 hypotension 58 31 very rare (1%) Very rare (<4-1%) HP:0002615
41 liver abscess 58 31 very rare (1%) Very rare (<4-1%) HP:0100523
42 budd-chiari syndrome 58 31 very rare (1%) Very rare (<4-1%) HP:0002639
43 vomiting 58 Frequent (79-30%)
44 hepatic fibrosis 58 Very frequent (99-80%)
45 abnormality of the liver 58 Very frequent (99-80%)
46 elevated alpha-fetoprotein 58 Very frequent (99-80%)
47 hepatocellular carcinoma 31 HP:0001402
48 abnormality of the hepatic vasculature 58 Very frequent (99-80%)
49 portal vein thrombosis 58 Frequent (79-30%)
50 abnormality of the rectum 58 Frequent (79-30%)

Symptoms via clinical synopsis from OMIM®:

57 (Updated 20-May-2021)
Abdomen Liver:
hepatocellular carcinoma
micronodular cirrhosis
subacute progressive viral hepatitis

Laboratory Abnormalities:
often integrated hbv sequences in hepatocellular carcinomas

Neoplasia:
primary liver cancer

Clinical features from OMIM®:

114550 (Updated 20-May-2021)

UMLS symptoms related to Hepatocellular Carcinoma:


nausea and vomiting; constipation; fever; abdominal pain; diarrhea; hepatosplenomegaly; dyspepsia; icterus; heartburn; gastrointestinal gas; malaise

MGI Mouse Phenotypes related to Hepatocellular Carcinoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.17 APC CASP8 CTNNB1 MET PIK3CA TERT

Drugs & Therapeutics for Hepatocellular Carcinoma

Drugs for Hepatocellular Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 595)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ethiodized oil Approved, Investigational Phase 4 8008-53-5
2
Tegafur Approved, Investigational Phase 4 17902-23-7 5386
3
Trastuzumab Approved, Investigational Phase 4 180288-69-1 9903
4
Raltitrexed Approved, Investigational Phase 4 112887-68-0 104758
5
Nadolol Approved Phase 4 42200-33-9 39147
6
Peginterferon alfa-2a Approved, Investigational Phase 4 198153-51-4 5360545
7
acetic acid Approved Phase 4 64-19-7 176
8
Cefazolin Approved Phase 4 25953-19-9 656510 33255
9
Ethanol Approved Phase 4 64-17-5 702
10
Atropine Approved, Vet_approved Phase 4 5908-99-6, 51-55-8 174174
11
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
12
Bevacizumab Approved, Investigational Phase 4 216974-75-3
13
Iodine Approved, Investigational Phase 4 7553-56-2 807
14
Nicotine Approved Phase 4 54-11-5 942 89594
15
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
16
Bupropion Approved Phase 4 34911-55-2, 34841-39-9 444
17
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
18
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
19
Povidone Approved Phase 4 9003-39-8 131751496
20
Chlorhexidine Approved, Vet_approved Phase 4 55-56-1 9552079 2713
21
Povidone-iodine Approved Phase 4 25655-41-8
22
Entecavir Approved, Investigational Phase 4 142217-69-4 153941
23
Propranolol Approved, Investigational Phase 4 525-66-6 4946
24
Acetaminophen Approved Phase 4 103-90-2 1983
25
Iron Approved Phase 4 7439-89-6 23925 29936
26
Edetic Acid Approved, Vet_approved Phase 4 60-00-4, 62-33-9 6049
27
Pentetic acid Approved Phase 4 67-43-6
28
Norepinephrine Approved Phase 4 51-41-2 439260
29
Velpatasvir Approved, Investigational Phase 4 1377049-84-7 67683363
30
Nitric Oxide Approved Phase 4 10102-43-9 145068
31
Azathioprine Approved Phase 4 446-86-6 2265
32
Coal tar Approved Phase 4 8007-45-2
33
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
34
Dalteparin Approved Phase 4 9005-49-6
35
Heparin Approved, Investigational Phase 4 9005-49-6 772 9812414
36
Tinzaparin Approved Phase 4 9041-08-1, 9005-49-6 25244225
37
Enoxaparin Approved Phase 4 9005-49-6 772
38
Cysteine Approved, Nutraceutical Phase 4 52-90-4 5862
39
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 6221 5280795
40
Thymalfasin Investigational Phase 4 62304-98-7
41
Cadexomer iodine Experimental Phase 4 94820-09-4
42
Clevudine Investigational Phase 4 163252-36-6
43
Tenofovir Experimental, Investigational Phase 4 147127-20-6 464205
44
Pirarubicin Investigational Phase 4 72496-41-4
45
Chlorotrianisene Investigational, Withdrawn Phase 4 569-57-3 11289
46 Calamus Phase 4
47 Bufanolides Phase 4
48 Sympatholytics Phase 4
49
Retinol acetate Phase 4 127-47-9 10245972
50 Pharmaceutical Solutions Phase 4

Interventional clinical trials:

(show top 50) (show all 2747)
# Name Status NCT ID Phase Drugs
1 Radiotherapy as an Adjuvant Therapy After Radiofrequency Ablation for Hepatocellular Carcinoma Unknown status NCT00557024 Phase 4
2 Transcatheter Arterial Chemoembolization as an Adjuvant Therapy After Radiofrequency Ablation for Hepatocellular Carcinoma Unknown status NCT00556803 Phase 4
3 Nucleoid as an Adjuvant Therapy After Radiofrequency Ablation for Hepatocellular Carcinoma Unknown status NCT00555334 Phase 4 lamivudine or entecavir
4 Efficacy of Antiviral Therapy With Lamivudine or Entecavir After Radical Resection for Hepatitis B Virus-Related Hepatocellular Carcinoma Unknown status NCT00768157 Phase 4 antiviral treatment (lamivudine or entecavir)
5 Transarterial Radioembolization Versus Chemoembolization for the Treatment of Advanced Hepatocellular Carcinoma Unknown status NCT02729506 Phase 4
6 Xihuang Capsules Prevention of Recurrence in Patients With Hepatocellular Carcinoma After Hepatectomy: A Multicenter Randomized Controlled Trial Unknown status NCT02399033 Phase 4 Xihuang Capsules
7 Effect of Preoperative Administration of Oral Pregabalin on the Postoperative Analgesia in Patients Scheduled for Radiofrequency Ablationof Focal Lesions in the Liver Unknown status NCT03151213 Phase 4 Pregabalin 150mg
8 Laparoscopic Surgery Versus Radiofrequency Ablation for Recurrent Hepatocellular Carcinoma After Initial Partial Hepatectomy: A Multicenter Experience Unknown status NCT02535117 Phase 4
9 An Randomized and Controlled Study of Hepatic Arterial Infusion of Oxaliplatin and Fluorouracil Treatment of Advanced Primary Liver Cancer After TACE Unknown status NCT02557503 Phase 4 Oxaliplatin and fluorouracil
10 Clinical Trial of Cinobufacini Combined With Transarterial Chemoembolization (TACE) on Primary Liver Cancer Unknown status NCT03843229 Phase 4 Cinobufacini injection;cinobufacini tablet
11 A Randomized Tril of Endoscopic Cyanoacrylate Obliteration vs. Nadolol Unknown status NCT00567216 Phase 4 Nadolol
12 Post-hepatectomy Adjuvant Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma Patients With Preoperative CTC Level ≥2: a Multicenter Randomized Controlled Trial in China Unknown status NCT02631499 Phase 4 Epirubicin;lipiodol
13 A Phase 4, Open-Label Study to Investigate the Efficacy and Safety of Tenofovir Disoproxil Fumarate (Viread(R)) in Preventing Hepatocellular Carcinoma Recurrence in Chronic Hepatitis B Virus Infected Patients With Low Viral Load at Baseline Treated With Radiofrequency Ablation or Resection Unknown status NCT02308319 Phase 4 Tenofovir disoproxil fumarate
14 Trial of Ablation of Small Hepatocellular Carcinomas in Patients of Cirrhosis Unknown status NCT01438437 Phase 4
15 Prophylactic Administration of Antibiotics Before Radiofrequency Ablation for Hepatocellular Carcinoma: A Randomized Trial Unknown status NCT02534961 Phase 4 Cefazolin
16 The Observation Of Safety And Survival Of Hepatocellular Carcinoma After Transcatheter Arterial Chemoembolization Combined With Anti-hepatitis B Virus Therapy Unknown status NCT01102335 Phase 4 Telbivudine
17 Radiofrequency Ablation Combined With Transcatheter Arterial Chemoembolization Versus Radiofrequency Ablation Alone for Recurrent Hepatocellular Carcinoma Unknown status NCT01415063 Phase 4
18 Radiofrequency Ablation vs. Hepatic Resection for the Treatment of Hepatocellular Carcinomas Smaller Than 2 cm.A Prospective and Randomized Clinical Trial Unknown status NCT01351194 Phase 4
19 Hepatic Resection Versus Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma Complicated by Portal Vein Tumor Thrombosis.A Prospective and Randomized Clinical Trial Unknown status NCT01350206 Phase 4
20 Radiofrequency Ablation With or With Transcatheter Arterial Embolization for Hepatocellular Carcinoma Unknown status NCT00554905 Phase 4
21 Phase4, to Assess Time to Progression (TTP) and Safety Profile of Doxorubicin-Eluting-Bead Embolization(DEBDOX) in Patients With Advanced HCC Unknown status NCT02525380 Phase 4
22 Radiofrequency Ablation Versus Liver Resection for Elderly Patients With Hepatocellular Carcinoma (HCC) Within the Milan Criteria Unknown status NCT01570075 Phase 4
23 Investigator Initiated Study of Thymosin in HBV-related HCC Unknown status NCT02281266 Phase 4 thymalfasin;nucleoside analog (suggest to use entecavir)
24 A Prospective Randomized Control Study of Cidan Capsule Combined With Transcatheter Arterial Chemoembolization in Hepatocellular Carcinoma Unknown status NCT02253511 Phase 4 Cidan capsule
25 Chemoembolization With or Without Antiviral Therapy for Unresectable HBV-related Hepatocellular Carcinoma With Low HBV DNA Replication: Effectiveness and Safety. A Prospective and Randomized Clinical Trial Unknown status NCT01894269 Phase 4 Lamivudine 100mg once daily; or Entecavir 0.5mg once daily.
26 A Randomized Controled Trial of Oral S-1 in Combination With Sequential Hepatic Arterial Infusion of Oxaliplatin After Transarterial Chemoembolization in Patients With Advanced Hepatocellular Carcinoma Unknown status NCT01997957 Phase 4 S-1
27 Effects of Different Inhalational Anesthetic Agents on the Incidence of Clinical and Subclinical Acute Kidney Injury After Liver Resection Surgery: a Pilot Study Unknown status NCT02174575 Phase 4 Sevoflurane;Desflurane
28 Hepatic Resection Versus Transarterial Chemoembolization as the Initial Treatment for Resectable Hepatocellular Carcinoma Beyond Milan Criteria Unknown status NCT02138981 Phase 4
29 The Response and Outcomes of Pegylated Interferon Plus Ribavirin Combination Therapy for Chronic Hepatitis C Patients Concomitant With Hepatocellular Carcinoma Unknown status NCT00834860 Phase 4 peginterferon alpha-2a and ribavirin
30 A Clinical Trail of Iodine[131I] Metuximab Injection With CIK Cells for Preventing Relapse and Metastasis of Hepatocellular Carcinoma Unknown status NCT01758679 Phase 4
31 A Prospective, Randomized, Multicenter, Open-label, Exploratory Study of Utilizing of Peginterferon Alfa-2a on the Relapse Rate of the Subjects With Hepatocellular Carcinoma Who Have Been Treated by Resection Unknown status NCT03253250 Phase 4 ETV;TDF;ADV;Peginterferon Alfa-2a
32 G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor: a Prospective, Multicentre, Randomised Controlled Trial Unknown status NCT02933333 Phase 4
33 Study of Cetuximab in Combination With Chemotherapy for the First Treatment of Metastatic Colorectal Cancer Unknown status NCT01564810 Phase 4 Cetuximab;chemotherapy of mFOLFOX6 or FOLFIRI
34 TAC vs TACE Plus folfox4 as the Treatment of Unresectalbe Liver Metastasis of Colorectal Cancer With Resection of the Primary Tumor: a Prospective, Randomized, Control Trial Unknown status NCT00868569 Phase 4
35 Study of New Adjuvant Chemotherapy of Non Resectable Liver Metastasis of Colorectal Cancer Without Bleeding, Obstruction Unknown status NCT01307878 Phase 4 chemotherapy ± targeted therapy
36 A Randomized Controlled Trial of TACE Hepatic Artery Infusion of Oxaliplatin and Raltitrexed Treatment of Colorectal Cancer With Liver Metastases Unknown status NCT02557490 Phase 4 oxaliplatin and raltitrexed
37 Phase IV Multi-Institutional Randomized Trial of Capecitabine Plus Oxaliplatin With Herceptin in Patients With Potentially Resectable HER-2 Positive Gastric Cancer With Liver Metastasis Unknown status NCT02380131 Phase 4 Oxaliplatin plus Capecitabine;Herceptin
38 Phase IV Multi-Institutional Randomized Trial of Capecitabine Plus Oxaliplatin With Bevacizumab in Patients With Potentially Resectable Gastric Cancer With Liver Metastasis Unknown status NCT01962376 Phase 4 Oxaliplatin;Capecitabine;Oxaliplatin;Capecitabine;Bevacizumab
39 A Prospective,Randomized Control Trial of Intraoperative Intraportal Chemotherapy (5-FU and Oxaliplatin) Combined With Adjuvant Chemotherapy to Prevent Liver Metastasis in Patients Receiving Curative Colorectal Cancer Resection. Unknown status NCT01972503 Phase 4 5-FU and oxaliplatin
40 Atropine for Prevention of Dysrhythmias Caused by Percutaneous Ethanol Instillation for Hepatoma Therapy Completed NCT00575523 Phase 4 Atropine;Placebo
41 Transarterial Chemoembolization Versus Best Support for Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis Completed NCT00646100 Phase 4
42 Multicenter Registry of Chemoembolization Using Drug-eluting Bead in Patients With Unresectable Hepatocellular Carcinoma Completed NCT01332669 Phase 4
43 Preventive Effect of Celecoxib on Sorafenib-related Hand Foot Syndrome Completed NCT02961998 Phase 4 Celecoxib;Sorafenib
44 Phase 4 Study of Peg-interferon Plus Ribavirin Therapy for Prevention of Hepatocellular Carcinoma Completed NCT00375661 Phase 4 interferon-alfa-2b and ribavirin
45 Qidong Hepatitis B Intervention Study Completed NCT00222664 Phase 4
46 A Prospective, Multi-center, Cohort Study to Evaluate the Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) Therapy in Chinese Chronic Hepatitis B (CHB) Subjects With Advanced Fibrosis & Compensated Cirrhosis Completed NCT02224456 Phase 4 Tenofovir disoproxil fumarate
47 Immune Profile and Prognosis of Malignant Liver Tumors With Radiofrequency Ablation (RFA) Therapy Completed NCT04707547 Phase 4
48 Treatment of Hepatocellular Carcinoma (HCC)by Selective Traditional Chemoembolization(TACE)Versus Selective TACE Via Microspheres Loaded With Doxorubicin: a Multicentre,Randomized,Open Label,Controlled Study. Completed NCT00936689 Phase 4
49 Magnetic Resonance With Gadoxetic Acid for the Diagnosis of Hepatocellular Carcinoma in Patients With Liver Cirrhosis. Evaluation of Its Impact for the Non-invasive Diagnosis Completed NCT01575574 Phase 4 GADOXETIC ACID
50 Diagnostic Contribution of XENETIX® CT PERFUSION in Pre-therapeutical Assessment of Hepatocellular Carcinoma Completed NCT01639703 Phase 4 Xenetix-CT perfusion imaging

Search NIH Clinical Center for Hepatocellular Carcinoma

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Interferon Alfa-2a
Interferon Alfa-2b
INTERFERON ALFA-3N,HUMAN LEUKOCYTE DERIVED
interferon alfacon-1
Interferon gamma-1b
Interferons
peginterferon alfa-2a
peginterferon alfa-2b
Recombinant interferon beta-1a
Recombinant interferon beta-1b
regorafenib
sorafenib

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Hepatocellular Carcinoma cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Hepatocellular Carcinoma:
Tumor infiltrating lymphocytes (TILs) for solid tumors
Embryonic/Adult Cultured Cells Related to Hepatocellular Carcinoma:
Tumor infiltrating lymphocytes PMIDs: 24329789 19342963 21498393 22996367 19304471 22555974 15800326 23650429 21325070 8170938 12242449 24218514 23904171

Cochrane evidence based reviews: liver neoplasms

Genetic Tests for Hepatocellular Carcinoma

Genetic tests related to Hepatocellular Carcinoma:

# Genetic test Affiliating Genes
1 Hepatocellular Carcinoma 29 APC AXIN1 CASP8 CTNNB1 IGF2R MET PDGFRL PIK3CA TP53

Anatomical Context for Hepatocellular Carcinoma

The Foundational Model of Anatomy Ontology organs/tissues related to Hepatocellular Carcinoma:

19
Liver

MalaCards organs/tissues related to Hepatocellular Carcinoma:

40
Liver, T Cells, Bone, Colon, Lung, Endothelial, Neutrophil

Publications for Hepatocellular Carcinoma

Articles related to Hepatocellular Carcinoma:

(show top 50) (show all 50933)
# Title Authors PMID Year
1
PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. 54 6 57
15608678 2005
2
MicroRNA expression, survival, and response to interferon in liver cancer. 61 47 57
19812400 2009
3
Somatic mutations of the APC gene in sporadic hepatoblastomas. 57 6
8764128 1996
4
Inducing and exploiting vulnerabilities for the treatment of liver cancer. 57 61
31578521 2019
5
Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma. 61 57
30814741 2019
6
Necroptosis microenvironment directs lineage commitment in liver cancer. 61 57
30209397 2018
7
Telomerase reverse transcriptase germline mutations and hepatocellular carcinoma in patients with nonalcoholic fatty liver disease. 6 61
28677271 2017
8
Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma. 61 57
24578576 2014
9
Mutant p53 expression enhances drug resistance in a hepatocellular carcinoma cell line. 6 61
15004724 2004
10
Gain of imprinting at chromosome 11p15: A pathogenetic mechanism identified in human hepatocarcinomas. 57 54
10779553 2000
11
AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. 6 54
10700176 2000
12
Beta-catenin mutations in hepatocellular carcinoma correlate with a low rate of loss of heterozygosity. 54 6
10435629 1999
13
Molecular basis of severe gynecomastia associated with aromatase expression in a fibrolamellar hepatocellular carcinoma. 61 57
9589695 1998
14
Susceptibility to hepatocellular carcinoma is associated with genetic variation in the enzymatic detoxification of aflatoxin B1. 57 54
7892276 1995
15
Mutational hotspot in the p53 gene in human hepatocellular carcinomas. 6 54
1849234 1991
16
Loss of heterozygosity suggests tumor suppressor gene responsible for primary hepatocellular carcinoma. 57 61
2573067 1989
17
Regional mapping to 4q32.1 by in situ hybridization of a DNA domain rearranged in human liver cancer. 57 61
2847975 1988
18
The diagnostic value of dual-phase cone-beam CT during hepatic arteriography in transarterial chemoembolization for hepatocellular carcinoma. 42 61
33761647 2021
19
Prognostic significance of postoperative change of PALBI grade for patients with hepatocellular carcinoma after hepatectomy. 42 61
33725934 2021
20
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. 6
26619011 2016
21
Reactivation of multipotency by oncogenic PIK3CA induces breast tumour heterogeneity. 6
26266985 2015
22
PIK3CA(H1047R) induces multipotency and multi-lineage mammary tumours. 6
26266975 2015
23
Prospective enterprise-level molecular genotyping of a cohort of cancer patients. 6
25157968 2014
24
Oncofetal gene SALL4 in aggressive hepatocellular carcinoma. 57
24047069 2013
25
Oncofetal gene SALL4 in aggressive hepatocellular carcinoma. 57
24047070 2013
26
Oncofetal gene SALL4 in aggressive hepatocellular carcinoma. 57
24047071 2013
27
Oncofetal gene SALL4 in aggressive hepatocellular carcinoma. 57
23758232 2013
28
Somatic gain-of-function mutations in PIK3CA in patients with macrodactyly. 6
23100325 2013
29
Liver transplantation for hepatocellular carcinoma in a patient with a novel telomerase mutation and steatosis. 6
23000435 2013
30
Exome sequencing of hepatitis B virus-associated hepatocellular carcinoma. 57
22922871 2012
31
Somatic mosaic activating mutations in PIK3CA cause CLOVES syndrome. 6
22658544 2012
32
Mosaic overgrowth with fibroadipose hyperplasia is caused by somatic activating mutations in PIK3CA. 6
22729222 2012
33
Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma. 57
21822264 2011
34
Genome-wide association study identifies a susceptibility locus for HCV-induced hepatocellular carcinoma. 57
21499248 2011
35
Genome-wide association study identifies 1p36.22 as a new susceptibility locus for hepatocellular carcinoma in chronic hepatitis B virus carriers. 57
20676096 2010
36
Chromosomal and genetic alterations in human hepatocellular adenomas associated with type Ia glycogen storage disease. 57
19762333 2009
37
MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib. 47 61
19726678 2009
38
MicroRNA-500 as a potential diagnostic marker for hepatocellular carcinoma. 47 61
19863192 2009
39
Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. 47 61
19617899 2009
40
Role of microRNA-155 at early stages of hepatocarcinogenesis induced by choline-deficient and amino acid-defined diet in C57BL/6 mice. 47 61
19711427 2009
41
Identification of microRNA-181 by genome-wide screening as a critical player in EpCAM-positive hepatic cancer stem cells. 61 47
19585654 2009
42
Identification of genes conferring resistance to 5-fluorouracil. 57
19622726 2009
43
Diet-induced hepatocellular carcinoma in genetically predisposed mice. 57
19454484 2009
44
MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells. 54 47
19584283 2009
45
MicroRNA-23b mediates urokinase and c-met downmodulation and a decreased migration of human hepatocellular carcinoma cells. 54 47
19490101 2009
46
miR-34a inhibits migration and invasion by down-regulation of c-Met expression in human hepatocellular carcinoma cells. 54 47
19006648 2009
47
Astrocyte elevated gene-1 regulates hepatocellular carcinoma development and progression. 57
19221438 2009
48
Upregulation of miR-23a approximately 27a approximately 24 decreases transforming growth factor-beta-induced tumor-suppressive activities in human hepatocellular carcinoma cells. 47 61
18508316 2008
49
Profiling microRNA expression in hepatocellular carcinoma reveals microRNA-224 up-regulation and apoptosis inhibitor-5 as a microRNA-224-specific target. 61 47
18319255 2008
50
Epidermal growth factor gene functional polymorphism and the risk of hepatocellular carcinoma in patients with cirrhosis. 57
18167406 2008

Variations for Hepatocellular Carcinoma

ClinVar genetic disease variations for Hepatocellular Carcinoma:

6 (show top 50) (show all 354)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 SET NM_003011.4(SET):c.701A>G (p.Glu234Gly) SNV other 438787 rs768759521 GRCh37: 9:131456212-131456212
GRCh38: 9:128693933-128693933
2 CTNNB1 NM_001904.4(CTNNB1):c.121A>G (p.Thr41Ala) SNV Pathogenic, other 17580 rs121913412 GRCh37: 3:41266124-41266124
GRCh38: 3:41224633-41224633
3 CTNNB1 NM_001904.4(CTNNB1):c.84_95del (p.Gln28_Asp32delinsHis) Deletion other 438756 rs1553630102 GRCh37: 3:41266086-41266097
GRCh38: 3:41224595-41224606
4 ARID1A NM_006015.6(ARID1A):c.6259G>A (p.Gly2087Arg) SNV other 438750 rs1553153748 GRCh37: 1:27106648-27106648
GRCh38: 1:26780157-26780157
5 MN1 NM_002430.3(MN1):c.912_914GCA[5] (p.Gln309del) Microsatellite other 438776 rs747503495 GRCh37: 22:28195603-28195605
GRCh38: 22:27799615-27799617
6 CTNNB1 NM_001904.4(CTNNB1):c.101G>T (p.Gly34Val) SNV Pathogenic 17582 rs28931589 GRCh37: 3:41266104-41266104
GRCh38: 3:41224613-41224613
7 CTNNB1 NM_001904.4(CTNNB1):c.1041_1044del (p.Val349fs) Deletion Pathogenic 801961 rs1575320216 GRCh37: 3:41268801-41268804
GRCh38: 3:41227310-41227313
8 APC NM_000038.6(APC):c.1695del (p.Val566fs) Deletion Pathogenic 840 rs397514032 GRCh37: 5:112164620-112164620
GRCh38: 5:112828923-112828923
9 PDGFRL PDGRL, 2-BP DEL Deletion Pathogenic 5469 GRCh37:
GRCh38:
10 AXIN1 NM_003502.4(AXIN1):c.1085_1116del (p.Val362fs) Deletion Pathogenic 6037 rs587776627 GRCh37: 16:359973-360004
GRCh38: 16:309973-310004
11 CASP8 NM_001372051.1(CASP8):c.1226_1227GT[1] (p.Val410fs) Microsatellite Pathogenic 7761 rs587776665 GRCh37: 2:202149961-202149962
GRCh38: 2:201285238-201285239
12 IGF2R NM_000876.3(IGF2R):c.4346G>T (p.Gly1449Val) SNV Pathogenic 14795 rs121434587 GRCh37: 6:160490993-160490993
GRCh38: 6:160069961-160069961
13 IGF2R NM_000876.3(IGF2R):c.4391G>A (p.Gly1464Glu) SNV Pathogenic 14796 rs121434588 GRCh37: 6:160491038-160491038
GRCh38: 6:160070006-160070006
14 TERT NM_198253.3(TERT):c.2004G>C (p.Glu668Asp) SNV Pathogenic 268081 rs1554040964 GRCh37: 5:1279532-1279532
GRCh38: 5:1279417-1279417
15 TERT NM_198253.3(TERT):c.337dup (p.Glu113fs) Duplication Pathogenic 268078 rs1554043088 GRCh37: 5:1294663-1294664
GRCh38: 5:1294548-1294549
16 APC NM_000038.6(APC):c.4183A>T (p.Ser1395Cys) SNV Pathogenic 817 rs137854578 GRCh37: 5:112175474-112175474
GRCh38: 5:112839777-112839777
17 TP53 NM_000546.6(TP53):c.747G>T SNV Pathogenic 12352 rs28934571 GRCh37: 17:7577534-7577534
GRCh38: 17:7674216-7674216
18 TP53 NM_000546.5(TP53):c.469G>T (p.Val157Phe) SNV Pathogenic 12353 rs121912654 GRCh37: 17:7578461-7578461
GRCh38: 17:7675143-7675143
19 TP53 NM_000546.5(TP53):c.722C>T (p.Ser241Phe) SNV Pathogenic 12359 rs28934573 GRCh37: 17:7577559-7577559
GRCh38: 17:7674241-7674241
20 PIK3CA NM_006218.4(PIK3CA):c.3203dup (p.Asn1068fs) Duplication Pathogenic 13658 rs587776802 GRCh37: 3:178952146-178952147
GRCh38: 3:179234358-179234359
21 CTNNB1 NM_001904.4(CTNNB1):c.94G>T (p.Asp32Tyr) SNV Pathogenic 17581 rs28931588 GRCh37: 3:41266097-41266097
GRCh38: 3:41224606-41224606
22 APC NM_000038.6(APC):c.1660C>T (p.Arg554Ter) SNV Pathogenic 807 rs137854573 GRCh37: 5:112164586-112164586
GRCh38: 5:112828889-112828889
23 APC NM_000038.6(APC):c.2805C>A (p.Tyr935Ter) SNV Pathogenic 810 rs137854575 GRCh37: 5:112174096-112174096
GRCh38: 5:112838399-112838399
24 APC NM_000038.6(APC):c.3867T>A (p.Cys1289Ter) SNV Pathogenic 545962 rs1554085355 GRCh37: 5:112175158-112175158
GRCh38: 5:112839461-112839461
25 CTNNB1 NM_001904.4(CTNNB1):c.1494dup (p.His499fs) Duplication Pathogenic 499655 rs1553631896 GRCh37: 3:41275327-41275328
GRCh38: 3:41233836-41233837
26 CTNNB1 NM_001904.4(CTNNB1):c.999C>A (p.Tyr333Ter) SNV Pathogenic 450550 rs778624338 GRCh37: 3:41268761-41268761
GRCh38: 3:41227270-41227270
27 TP53 NM_000546.5(TP53):c.559+1G>A SNV Pathogenic 428908 rs1131691042 GRCh37: 17:7578370-7578370
GRCh38: 17:7675052-7675052
28 TP53 NM_000546.6(TP53):c.524G>A (p.Arg175His) SNV Pathogenic 12374 rs28934578 GRCh37: 17:7578406-7578406
GRCh38: 17:7675088-7675088
29 TP53 NM_000546.5(TP53):c.96+1G>T SNV Pathogenic 482212 rs1131691003 GRCh37: 17:7579699-7579699
GRCh38: 17:7676381-7676381
30 APC NM_000038.6(APC):c.70C>T (p.Arg24Ter) SNV Pathogenic 184702 rs145945630 GRCh37: 5:112090657-112090657
GRCh38: 5:112754960-112754960
31 APC NM_000038.6(APC):c.637C>T (p.Arg213Ter) SNV Pathogenic 140952 rs587781392 GRCh37: 5:112116592-112116592
GRCh38: 5:112780895-112780895
32 APC NM_000038.6(APC):c.646C>T (p.Arg216Ter) SNV Pathogenic 127312 rs62619935 GRCh37: 5:112128143-112128143
GRCh38: 5:112792446-112792446
33 APC NM_000038.6(APC):c.694C>T (p.Arg232Ter) SNV Pathogenic 42248 rs397515734 GRCh37: 5:112128191-112128191
GRCh38: 5:112792494-112792494
34 APC NM_000038.6(APC):c.847C>T (p.Arg283Ter) SNV Pathogenic 184999 rs786201856 GRCh37: 5:112151204-112151204
GRCh38: 5:112815507-112815507
35 APC NM_000038.6(APC):c.933+1G>A SNV Pathogenic 233970 rs876660765 GRCh37: 5:112151291-112151291
GRCh38: 5:112815594-112815594
36 CTNNB1 NM_001904.4(CTNNB1):c.283C>T (p.Arg95Ter) SNV Pathogenic 265443 rs775104326 GRCh37: 3:41266486-41266486
GRCh38: 3:41224995-41224995
37 TP53 NM_000546.6(TP53):c.818G>A (p.Arg273His) SNV Pathogenic 12366 rs28934576 GRCh37: 17:7577120-7577120
GRCh38: 17:7673802-7673802
38 TP53 NM_000546.6(TP53):c.743G>A (p.Arg248Gln) SNV Pathogenic 12356 rs11540652 GRCh37: 17:7577538-7577538
GRCh38: 17:7674220-7674220
39 PIK3CA NM_006218.4(PIK3CA):c.3139C>T (p.His1047Tyr) SNV Pathogenic 39705 rs121913281 GRCh37: 3:178952084-178952084
GRCh38: 3:179234296-179234296
40 PIK3CA NM_006218.4(PIK3CA):c.3140A>G (p.His1047Arg) SNV Pathogenic/Likely pathogenic 13652 rs121913279 GRCh37: 3:178952085-178952085
GRCh38: 3:179234297-179234297
41 CTNNB1 NM_001904.4(CTNNB1):c.134C>T (p.Ser45Phe) SNV Pathogenic/Likely pathogenic 17588 rs121913409 GRCh37: 3:41266137-41266137
GRCh38: 3:41224646-41224646
42 CTNNB1 NM_001904.4(CTNNB1):c.133T>C (p.Ser45Pro) SNV Pathogenic/Likely pathogenic 17589 rs121913407 GRCh37: 3:41266136-41266136
GRCh38: 3:41224645-41224645
43 PIK3CA NM_006218.4(PIK3CA):c.1634A>C (p.Glu545Ala) SNV Pathogenic/Likely pathogenic 13659 rs121913274 GRCh37: 3:178936092-178936092
GRCh38: 3:179218304-179218304
44 TP53 NM_000546.5(TP53):c.517G>A (p.Val173Met) SNV Likely pathogenic 233951 rs876660754 GRCh37: 17:7578413-7578413
GRCh38: 17:7675095-7675095
45 GNAS NM_000516.6(GNAS):c.601C>T (p.Arg201Cys) SNV Likely pathogenic 15933 rs11554273 GRCh37: 20:57484420-57484420
GRCh38: 20:58909365-58909365
46 GNAS NM_000516.6(GNAS):c.602G>T (p.Arg201Leu) SNV Likely pathogenic 210045 rs121913495 GRCh37: 20:57484421-57484421
GRCh38: 20:58909366-58909366
47 TP53 NM_000546.5(TP53):c.641A>G (p.His214Arg) SNV Likely pathogenic 376615 rs1057519992 GRCh37: 17:7578208-7578208
GRCh38: 17:7674890-7674890
48 GNAS NM_000516.6(GNAS):c.602G>A (p.Arg201His) SNV Likely pathogenic 15934 rs121913495 GRCh37: 20:57484421-57484421
GRCh38: 20:58909366-58909366
49 NRAS NM_002524.5(NRAS):c.182A>G (p.Gln61Arg) SNV Likely pathogenic 13900 rs11554290 GRCh37: 1:115256529-115256529
GRCh38: 1:114713908-114713908
50 CREBBP NM_004380.3(CREBBP):c.4336C>T (p.Arg1446Cys) SNV Likely pathogenic 95047 rs398124146 GRCh37: 16:3788618-3788618
GRCh38: 16:3738617-3738617

UniProtKB/Swiss-Prot genetic disease variations for Hepatocellular Carcinoma:

72 (show all 21)
# Symbol AA change Variation ID SNP ID
1 AXIN1 p.Leu106Arg VAR_015589
2 AXIN1 p.Pro345Leu